Explore our Cancer Prevention, High Risk & Early Detection Network for information regarding prevention, surveillance, screenings, assessments and more.
Hoag leads innovative clinical trials, including immunotherapy agents, all pushing for more advanced, effective care for gastric cancer patients.

Gastric cancer is term used to describe cancer that occurs in the stomach. The most common type of stomach cancer occurs within the mucus-producing cells on the inside lining of the stomach (adenocarcinoma). Over time, the cancer may invade more deeply into the stomach wall and may grow through the stomach’s outer layer into nearby organs, such as the liver, pancreas, esophagus, or intestine.
It’s important to note that over the decades true gastric cancer has continued to decline. However, cancers of the junction between the esophagus and stomach are increasing. These latter tumors appear to be more similar to esophageal cancers rather than true gastric cancer.
Signs and symptoms of gastric cancer may include:
Because gastric cancer symptoms are similar to many other gastrointestinal conditions, accurate evaluation is critical to ensure proper treatment. That’s why it’s important to seek care from a health care expert experienced in the complex diagnosis and treatment of gastric cancer and other gastrointestinal conditions.
The exact cause of gastric cancer is unknown. However, factors that may increase an individual’s risk of stomach cancer include:

Get care from medical providers that fit your needs in a location near you.
Find a providerFind information made to guide and support you on your journey. 
See all resourcesDidn’t see what you’re looking for? Reach out and we’ll make sure you get what you need. 
Contact usComprehensive evaluation with accurate diagnosis is the foundation for achieving highly successful outcomes. That’s why it’s important to seek care from a center that provides academic level care from a multidisciplinary, specialized team of gastrointestinal experts experienced in the accurate diagnosis of gastric cancer, as well as other complex gastrointestinal disorders.
Beginning with a thorough evaluation that includes a comprehensive physical exam, personal medical history review and state-of-the-art diagnostic workup, Hoag’s multidisciplinary team of board-certified, fellowship trained gastrointestinal experts carefully evaluate and pinpoint the nature of the issue, so the most appropriate personalized treatment options can be employed.
Hoag’s state-of-the-art diagnostic technologies provide our team with the latest modalities in the accurate diagnosis of gastric cancer and other disorders. Some of the progressive imaging studies that may be utilized include:
Upper Gastrointestinal Endoscopy is a minimally invasive procedure that allows a physician to look inside the esophagus, stomach, and duodenum (part of the small intestine). During an upper endoscopy, a thin, lighted tube called an endoscope is carefully guided down the esophagus. The endoscope transmits a high definition image to a monitor, so the physician can view the lining of these organs. Endoscopy allows physicians to visualize evidence of gastrointestinal disorders, as well as remove tissue samples for biopsy. Hoag surgeons typically perform the endoscopy themselves in order to assess how much of the stomach is involved for surgical planning.
Biopsy is the removal of a sample of tissue for testing. This procedure is performed to definitively diagnose gastric cancer, and usually takes place via endoscopy.
Computed Tomography (CT) utilizes state-of-the-art x-rays to help determine the extent of the cancer and whether it encompasses the surrounding organs.
Positron Emission Tomography (PET) is a nuclear medicine imaging technique which produces a three-dimensional image that helps determine the extent of the cancer and whether it has spread to the lymph nodes.
Endoscopic Ultrasound (EUS) is a specialized endoscope that also has ultrasound capabilities. EUS can evaluate and assess the size of the tumor, lymph node status and Stage of the tumor.
It’s important to note that proper diagnosis of gastric cancer is critical to developing a successful treatment plan. That’s why it’s so important to seek proper evaluation and treatment from a healthcare expert experienced in the most advanced gastrointestinal care.
When it comes to gastric cancer and other gastrointestinal conditions, Hoag provides a full array of progressive treatment options. As a recognized leader and high-volume provider of innovative gastrointestinal care, Hoag’s multidisciplinary team of digestive disease experts performs some of the most advanced gastroenterology procedures available in the nation with clinical outcomes that rival national figures.
Hoag continues to lead the way in complex GI care, providing access to a highly specialized surgical team that works collaboratively with Hoag thoracic surgeons, gastroenterologists and medical oncology specialists to provide expert care. Hoag’s committed to accurate diagnosis, combined with progressive therapeutic options enables Hoag patients to achieve some of the highest clinical outcomes in the nation.To schedule a comprehensive diagnostic evaluation, or a second-opinion consultation with a Hoag gastroesophageal expert, call us at: 888-566-9712.
Hoag is a high-volume referral center for complex gastrointestinal disorders. Hoag’s multidisciplinary team of gastroenterology experts works together to thoroughly review and determine the best treatment option suited to each individual patient. The team then carefully tailors a personalized treatment plan to effectively achieve the best possible outcome for the patient. This emphasis on a collaborative, comprehensive approach to patient-centered care is why Hoag patient outcomes rank are among the nation’s best.
Once gastric cancer is diagnosed, important staging tests are performed to determine if the cancer has spread, and if so, to what extent. The type of treatment recommended depends upon the stage of the cancer and may include options such as:
The standard of care for gastric cancer is surgical removal of the tumor with dissection of lymph node tissue around the surrounding structures. The amount of stomach removed depends on the size and location of the tumor. Surgery also removes as much of the lymph node tissue surrounding the stomach as possible to remove all potential regional sites of tumor spread and maximize the chance of cure.
When appropriate, minimally invasive techniques may be applied for the operation, such as state-of-the-art robotic and laparoscopic gastrectomy, which results in less scarring and discomfort, as well as a faster recovery time for the patient. The Hoag gastrointestinal surgical team has not only one of the highest volumes and expertise for innovative gastric cancer surgeries, but also the lowest morbidity and mortality rates.
Chemotherapy is the use of drugs to kill cancer cells. The drugs enter the bloodstream and travel through the body killing mostly cancer cells, but also some healthy cells. Chemotherapy is often combined with surgery in the treatment of gastric cancer. The utilization of chemotherapy is selective, and may be used before or after surgery.
Radiation therapy uses radiation to kill cancer cells and shrink tumors. On occasion, radiation therapy may also be necessary in the treatment of gastric cancer based upon the type/stage of cancer. As a nationally recognized leader in state-of-the-art radiation therapies, Hoag’s Radiation Oncology Program is yet another example of the institute’s commitment to excellence in innovative cancer treatment.
Targeted therapy uses drugs that attack specific abnormalities within cancer cells. The most common targeted therapies used to treat gastric cancer include:
Trastuzumab (Herceptin) for stomach cancer cells that produce too much HER2,
Imatinib (Gleevec) for a rare form of stomach cancer called gastrointestinal stromal tumor, and
Sunitinib (Sutent) for gastrointestinal stromal tumor.
Tests are performed on your cancer cells to help your physician to determine whether these targeted treatments are likely to work for you.
When it comes to seeking out the most advanced academic-level gastrointestinal care, there is no longer any need to travel long distances. Hoag offers the latest in state-of-the-art diagnosis and leading-edge treatment options that may not be readily available at other centers, including participation in clinical trials that helps to bring advanced gastrointestinal care to even more patients.
Perhaps the most distinguishing aspect of Hoag’s advanced treatment of gastrointestinal conditions is that in each and every case, treatment is always specifically tailored to the meet the unique needs of the individual patient.
The Hoag Digestive Disease Center continues to lead the way in complex gastrointestinal care, providing access to a highly specialized surgical team that works collaboratively with Hoag-affiliated GI and medical oncology specialists. Hoag’s committed to accurate diagnosis, combined with progressive therapeutic options enables Hoag patients to achieve some of the highest clinical outcomes in the nation.
To schedule a comprehensive diagnostic evaluation, or a second-opinion consultation with a Hoag gastroenterology expert, call us at 949-764-8379.

Katherine Blevins, M.D., Ph.D. is a minimally invasive surgeon (MIS) with a focus in bariatric, foregut and advanced gastrointestinal surgery. She is board certified in general surgery, and is fellowship trained in advanced GI, MIS and bariatric surgery. She holds certificates for Advanced GI MIS Surgery from SAGES, as well as the ASMBS Fellowship Certificate for Bariatric Surgery. She is skilled in both laparoscopic and robotic techniques. Dr. Blevins completed her general surgery residency training at Stanford University. During her training, she spent two years in professional development as a fellow in the Stanford Biodesign Innovation Fellowship, a project based medical technology innovation program where she was trained in medical technology innovation from idea to implementation. She completed advanced clinical training as a clinical fellow in advanced GI/MIS and Bariatric Surgery at Cedars Sinai Medical Center, one of the highest ranked fellowship programs for GI surgery in the country. Dr. Blevins’ research interests include medical technology innovation as well as patient outcomes after bariatric surgery. She has co-authored multiple peer-reviewed journal articles and book chapters and has directed and collaborated with teams in many stages of medical technology innovation. Dr. Blevins attended University of California, Irvine for her undergraduate education, where she earned a bachelor’s degree in biomedical engineering. She earned her doctorate degree in bioengineering with an emphasis in biomaterials from the University of Utah. Her dissertation focused on designing novel targeted gene delivery systems to prevent type 1 diabetes. During her Ph.D. work, she discovered her love for the translational aspects of research and chose to expand her background in clinical medicine. She attended medical school at the University of Utah where she was elected into Alpha Omega Alpha. During her clinical years, she was drawn to surgery. One of her favorite parts of surgery is the ability to work with patients to help solve their problems. Her long-term goals are to integrate clinical practice as a surgeon with advancing innovation in medical technology.

Ronald Wolf, M.D., F.A.C.S., is a board-certified surgical oncologist who specializes in treating liver, bile duct and pancreatic cancer at Hoag Family Cancer Institute. His clinical interests include pancreatic adenocarcinoma, colon and rectal cancers that have metastasized to the liver, surgical treatment for bile duct tumors and cysts and surgery for soft tissue sarcoma. Previously, Dr. Wolf served as Professor of Clinical Surgery in the Department of Surgery, Division of Hepatobiliary & Pancreas Surgery/Islet Cell Transplantation at UC Irvine School of Medicine and Long Beach Memorial Medical Center. Prior to that, he served as Medical Director of Hepatic and Pancreatic Surgery at Legacy Good Samaritan Medical Center in Portland, Oregon, and as the Medical Director of Liver and Pancreas Surgery at Providence Cancer Center, also in Portland. Dr. Wolf received his medical degree from Oregon Health & Science University in Portland, followed by an internship and two residencies in general surgery at UC Davis. He then completed a fellowship in surgical oncology at Memorial Sloan Kettering Cancer Center in New York, where he also served as a clinical research fellow. Later, he helped direct surgical resident and fellowship-level postgraduate training programs in Portland. Dr. Wolf has co-authored more than 80 clinical presentations throughout his career and is a committee member of several national organizations including the American College of Surgeons, the Society of Surgical Oncology and the AHPBA Americas Hepatopancreatobiliary Association.

<p>Tara Seery, M.D., attended University College Dublin School of Medicine followed by an internship at Mater Misericordiae Hospital as well as an internship and residency at Caritas St. Elizabeth Medical Center in Boston. She then completed fellowships in hematology/oncology at both Caritas St. Elizabeth Medical Center and University of Illinois at Chicago. Dr. Seery is board certified in Medical Oncology and Hematology.</p><p>Dr. Seery is particularly interested in GI oncology, including hepatobiliary cancers such as pancreatic, liver and bile duct cancers.</p><p>She has served as the primary investigator on several clinical research trials, co-authored numerous medical publications and abstracts, and edited multiple peer-reviewed journals. Additionally, she has given clinical presentations both across the U.S. and abroad. </p><p>Dr. Seery’s teaching experience spans the areas of medical and graduate level courses including a Hematology/Oncology Fellowship Annual Lecture Series on Pancreatic Cancer, Liver Cancer and the Management of Unresectable Hepatocellular Carcinoma at UC Irvine’s 5th Annual Gastroenterology and Hepatology Symposium. In addition, she oversaw a group of Hematology/Oncology Fellows at the University of California Irvine Outpatient Clinic.</p><p>Dr. Seery is a member of the American Society of Clinical Oncology and the American Society of Hematology.</p>

Medical Director of Cancer Research for Hoag Family Cancer Institute

Executive Medical Director, Hoag Digestive Health Institute

Medical Director of Hoag Advanced Endoscopy Center, Gastroenterologist

Dr. Kankotia is a board-certified gastroenterologist at the Hoag Digestive Health Institute. His focus is in advanced endoscopic procedures, and his clinical interests include pancreaticobiliary disease, tissue resection, Barrett’s esophagus, and bariatrics. Other services offered include luminal stenting, radiofrequency ablation, endoscopic mucosal resection, esophageal pH monitoring (Bravo), liver biopsy, portal pressure measurement, and endoscopic suturing. He strives to provide his patients and their families with personalized care plans that help each patient reach their health goals. At the Hoag Digestive Health Institute, Dr. Kankotia works with a team of digestive health experts to provide a comprehensive approach to wellness. Dr. Kankotia earned his medical degree at the Keck School of Medicine of the University of Southern California in Los Angeles. He completed internal medicine residency and gastroenterology fellowship at University of Southern California/LAC+USC Medical Center. He then completed an additional fellowship in advanced endoscopy at the University of Michigan in Ann Arbor, where he developed expertise in ERCP (endoscopic retrograde cholangiopancreatography), diagnostic and therapeutic EUS (endoscopic ultrasound), and other techniques while garnering experience managing complex cases. Dr. Kankotia is a current member of the American College of Gastroenterology, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy. Additionally, he has contributed to several publications on topics such as gastric cancer, biliary disease, pancreatic cysts, and luminal strictures.

Paul J. Korc, M.D. serves as medical director of the Hoag GI Lab and is a board-certified gastroenterologist with fellowship training in advanced endoscopic procedures. After completing his residency and fellowship at USC, he went on to spend a year at Indiana University, one of the nation’s top programs for biliary and pancreatic disorders. There, he received training in endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound (EUS), gaining extensive experience in the management of complex cases. Dr. Korc’s expertise also includes removal of large polyps and early stage cancers of the gastrointestinal tract, using endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD). He spent time in Seoul, Korea learning ESD, a cutting-edge technique in which pre-cancerous lesions and superficial cancers are removed en bloc (in one piece), avoiding the need for surgery. Additionally, Dr. Korc performs peroral endoscopic myotomy (POEM), a specialized procedure that restores the ability to eat and drink for people with achalasia, an esophageal motility disorder. Dr. Korc brings to Hoag his expertise in these procedures, some of which are available at only a handful of medical centers in Southern California. Dr. Korc offers patients compassionate, personalized care along with the very best advances in endoscopic treatment.
Hoag’s Precision Medicine Program combines genomics and genetics to diagnose, treat, and prevent diseases. Using the latest advances in genomic technologies, targeted therapies and research, our precision medicine program brings together a multidisciplinary team, including a robust genetic counseling group of experts, to provide patients with the latest in innovation and technology.
Being diagnosed with cancer can feel overwhelming at times. Many patients and their families need help with coping and can benefit from supportive counseling. Oncology Clinical Social Workers are available to provide emotional and practical support during all stages of cancer including diagnosis, treatment and post-treatment survivorship.
Hoag Family Cancer Institute dietitians work closely with patients’ physicians, nurses, therapists, and social workers to ensure complete care.